# Combination of Capecitabine and Oxaliplatin in Metastatic Nasopharyngeal Carcinoma

> **NCT00363831** · PHASE2 · UNKNOWN · sponsor: **The University of Hong Kong** · enrollment: 42 (estimated)

## Conditions studied

- Nasopharyngeal Neoplasms

## Interventions

- **DRUG:** Oxaliplatin

## Key facts

- **NCT ID:** NCT00363831
- **Lead sponsor:** The University of Hong Kong
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2006-07
- **Primary completion:** 2009-12
- **Final completion:** —
- **Target enrollment:** 42 (ESTIMATED)
- **Last updated:** 2010-07-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00363831

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00363831, "Combination of Capecitabine and Oxaliplatin in Metastatic Nasopharyngeal Carcinoma". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00363831. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*